Immunology company Nucleome Therapeutics announced on Monday the appointment of Dr Michelle Morrow as its chief scientific officer (CSO), effective 23 February 2026.

Dr Morrow has two decades of experience in drug discovery and development and executing R&D strategy across biotech and large pharma.

Most recently Dr Morrow was CSO at Avacta Therapeutics, providing strategic leadership of discovery and preclinical research and leading its oncology programme through candidate selection to IND approval. Earlier, she was SVP, head of invoX Therapeutics Innovation, following its acquisition of F-star Therapeutics.